Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.
about
Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.Prognostic factors and treatment of pediatric acute lymphoblastic leukemia.PharmGKB summary: methotrexate pathway.Contribution of tumoral and host solute carriers to clinical drug response.Genome-wide study of methotrexate clearance replicates SLCO1B1.Pain in Intellectually Disabled Children: Towards Evidence-Based Pharmacotherapy?Pharmacokinetics of Chemotherapeutic Drugs in Pediatric Patients With Down Syndrome and Leukemia.Optimizing drug development of anti-cancer drugs in children using modelling and simulation.Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.Uptake carriers and oncology drug safety.Challenges in implementing individualized medicine illustrated by antimetabolite therapy of childhood acute lymphoblastic leukemia.Acute lymphoblastic leukaemia in children with Down syndrome: an updated review.Child and adolescent Down syndrome-associated leukaemia: the Irish experience.Clinical presentation and risk factors of serious infections in children with Down syndrome treated for acute lymphoblastic leukemia.Hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia and Down syndrome.Seroprevalence of herpes virus associated with the presence and severity of oral mucositis in children diagnosed with acute lymphoid leukemia.Acute leukemia in children with Down syndrome.Outcomes of treatment for relapsed acute lymphoblastic leukaemia in children with Down syndrome.Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.Impact of oral mucositis on oral-health-related quality of life of patients diagnosed with cancer.Myelopathy mimicking subacute combined degeneration in a Down syndrome patient with methotrexate treatment for B lymphoblastic leukemia: report of an autopsy case.Acute lymphoblastic leukemia and Down syndrome: the collaborative study of the Tokyo Children's Cancer Study Group and the Kyushu Yamaguchi Children's Cancer Study Group.
P2860
Q33398162-C4608A3F-7533-42BB-B542-967F31A1C3EEQ33557148-C6D24B1B-37DE-40AC-970D-00397A486318Q33698398-5C378688-B0DE-4A89-A52A-5FFD6D0AFE4BQ33770150-ABB736F1-1A41-4149-86D5-553333146444Q35115680-0AB82C18-6246-4F01-8228-C952D19260D4Q35946876-7BDE0961-2B7E-44D6-9859-9A262965AABAQ36595293-D40784E0-9B4C-4429-8549-3F4D50FBE399Q36621626-2FFABEF8-CE40-45D4-8538-4DFADF8FB078Q36828315-83478097-2DEF-4399-B3C1-564BCA79F612Q36987975-11100644-F27B-429B-BCC9-9124AAC04443Q37429718-7D9ED4D1-5103-485D-9033-55E44883C329Q37663396-FE04E90B-B20A-4FF8-B619-D8D1361C70AEQ37929894-38B34F18-C380-41BF-87BC-7D5BE6E0A292Q37935867-760717FA-75EF-4565-9D71-AC1107A4275CQ38262596-9E9621B0-999C-42A4-BFCE-E8EE072CB9BFQ38892345-7C0CAB46-61BF-4CEA-A0DB-3879433DEF21Q41724174-DB2286C0-D5F1-4503-9428-8DFC916CCB9FQ42249954-D12592D1-F36F-4388-B6E5-5DEA5641CA04Q42739970-A73447D3-BEC2-4B02-BE15-41FFE81BD2B8Q45723589-6E032247-064C-4DB6-A3E8-D980CE2C1032Q47592832-6CFC1A51-F31C-4EA5-826B-D6B03574474AQ48061717-CD9BFB61-D721-42BC-8E9B-5BE5E7BFEAD3Q53060966-0BA1FCB1-A08A-4095-A684-A3D8FB4E01C1Q53270825-6B7A1116-650B-470B-A58C-CA735E55ED09
P2860
Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Methotrexate-induced side effe ...... acute lymphoblastic leukemia.
@ast
Methotrexate-induced side effe ...... acute lymphoblastic leukemia.
@en
type
label
Methotrexate-induced side effe ...... acute lymphoblastic leukemia.
@ast
Methotrexate-induced side effe ...... acute lymphoblastic leukemia.
@en
prefLabel
Methotrexate-induced side effe ...... acute lymphoblastic leukemia.
@ast
Methotrexate-induced side effe ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P1433
P1476
Methotrexate-induced side effe ...... acute lymphoblastic leukemia.
@en
P2093
C Michel Zwaan
Ron A A Mathôt
Trudy D Buitenkamp
Valerie de Haas
P2860
P304
P356
10.3324/HAEMATOL.2009.019778
P50
P577
2010-04-23T00:00:00Z